Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
Summary: Since the successful approval of gemtuzumab ozogamicin, antibody-drug conjugates (ADCs) have emerged as a pivotal category of targeted therapies for cancer. Among these ADCs, the use of monomethyl auristatin E (MMAE) as a payload is prevalent in the development of ADC drugs, which has signi...
Main Authors: | Zhiwen Fu, Chen Gao, Tingting Wu, Lulu Wang, Shijun Li, Yu Zhang, Chen Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223018552 |
Similar Items
-
Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates
by: Filip S. Ekholm, et al.
Published: (2018-12-01) -
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
by: Dina V. Hingorani, et al.
Published: (2022-07-01) -
Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
by: Yichen Wang, et al.
Published: (2018-08-01) -
Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug Conjugates against Breast Cancer
by: Meghdad Abdollahpour-alitappeh, et al.
Published: (2017-06-01) -
Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
by: Isabella Damiani, et al.
Published: (2021-08-01)